Endothelial progenitor cells in breast cancer patients

Richter-Ehrenstein, Christiane; Rentzsch, Jörn; Runkel, Sanyukta; Schneider, Achim; Schönfelder, Gilbert

doi:10.1007/s10549-007-9505-z

Cited by 34 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, we observed a significant correlation between the modulation of CD31 þ /VEGFR-2 þ and the likelihood of obtaining a clinical response, in that patients who responded to treatment did not experience an increase of this sub-population of CEC. CD31 þ /VEGFR-2 þ cells are crucial in the neovascularisation process and have recently been shown to be elevated in breast cancer patients to significantly correlate with tumour size and to rapidly decline after removal of the tumour, suggesting a possible induction by tumour-driven angiogenic stimuli (Richter-Ehrenstein et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

et al. 2008

View full text Add to dashboard Cite

The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer. We presently investigated the activity of bevacizumab in combination with chemotherapy, including capecitabine and vinorelbine, and endocrine therapy, including letrozole ( þ triptorelin in premenopausal women), as primary therapy for patients with ER and/or PgR X10% T2 -T4a-c, N0 -N2, M0 breast cancer. Biological end point included the proliferative activity (Ki67), whereas clinical end points were clinical response rate, pathological complete response (pCR) and tolerability. Circulating endothelial cells (CECs) and their progenitors, as surrogate markers of antiangiogenic activity, were measured at baseline and at surgery.Thirty-six women are evaluable. A clinical response rate of 86% (95% CI, 70 -95) and no pCR were observed; Ki67 was significantly decreased by 71% (interquartile range, À82%, À62%). Toxicity was manageable: two grade 3 hypertension, four grade 3 deep venous thrombosis and no grade 42 proteinuria were observed. Treatment significantly decreased the percentage of viable CECs and prevented the chemotherapy-induced mobilisation of circulating progenitors. Basal circulating progenitors were positively associated with clinical response. In conclusion, bevacizumab is feasible and active in association with primary chemoendocrine therapy for ER-positive tumours in terms of proliferation inhibition, clinical response and antiangiogenic activity.

show abstract

Section: Discussionmentioning

confidence: 99%

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

et al. 2008

View full text Add to dashboard Cite

show abstract

“…EPCs have a high proliferation potential and have been found to be a potential marker for neovascularisation and for the response to antiangiogenic therapies [4,5,10,13,14]. The role of EPCs in solid malignancies is less well studied than that of CECs.…”

Section: Discussionmentioning

confidence: 99%

“…Their conclusion was that since the mobilization of EPCs could contribute to tumor neovascularisation, early antiangiogenic therapy in combination with chemotherapy could be beneficial for successful treatment. Another recent study found elevated levels of EPCs in patients with breast cancer before therapy with a rapid decline after tumor excision [14]. Willett et al [15] investigated possible surrogate markers for antiangiogenic therapy with the vascular endothelial growth factor specific antibody bevacizumab in five rectal cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients

Brunner

Thurnher

Heiduschka

et al. 2008

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Numerous studies that only used FACS technique have been conducted to reveal the dynamics of CEPCs in various cancer types such as lung cancer [22,[52][53][54], malignant glioma [20,55,56], HCC [21,57], breast cancer [58,59], head and neck cancer [60], ovarian cancer [61][62][63], cervical cancer [63], colorectal cancer [64], prostate cancer [65], renal cell carcinoma (RCC) [66,67], osteosarcoma [68], and multiple myeloma [69] (Table 1). However, inconclusive and controversial results were obtained; although in most studies, a significantly higher EPCs concentration was observed in the peripheral blood of cancer patients.…”

Section: Circulating Levels Of Epcs In Cancer Patientsmentioning

confidence: 99%

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

et al. 2014

Med Oncol

View full text Add to dashboard Cite

Human cancers are endowed with sustained vascularization capability, and their growth, invasion, and metastasis are vascularization dependent. Recently, accumulated body of evidence suggests that endothelial progenitor cells (EPCs) can support vasculogenesis and induce angiogenesis through paracrine mechanisms. In addition, numerous clinical studies have revealed the increase in the number of EPCs in the peripheral blood of cancer patients and demonstrated the correlation of circulating EPCs (CEPCs) with the clinical outcomes. This review highlights current enrichment procedures and methods for the detection of CEPCs and different biomarkers to identify CEPCs as well as the functions of EPCs in tumor vascularization. Furthermore, we systematically review available studies on the clinical relevance of CEPCs in cancer patients to explore the potential diagnostic and prognostic values of CEPCs. Although several contrasting results exist, CEPCs can conceivably serve as a promising biomarker for the early diagnosis, prognosis prediction, and treatment response indication in the future. Additionally, further well-designed clinical studies with larger sample size and unique, specific enumeration procedures are warranted to achieve further insight into the clinical implications of CEPCs.

show abstract

Endothelial progenitor cells in breast cancer patients

Abstract: Our findings lead to the tumor, as source of angiogenic chemokines, is most important for recruiting CD34(+)FLK-1(+ )EPCs during breast cancer development. Therefore circulating endothelial progenitor cells may work as a new diagnostic tool in the screening and diagnosis of breast cancer.

Cited by 34 publications

References 25 publications

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity

Elevated levels of circulating endothelial progenitor cells in head and neck cancer patients

Circulating endothelial progenitor cell: a promising biomarker in clinical oncology

Contact Info

Product

Resources

About